NCT01869777View on ClinicalTrials.gov

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

NACompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 19, 2018

Study Completion Date

May 31, 2020

Conditions
Acute Undifferentiated LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Mast Cell LeukemiaMyeloid/NK-cell Acute LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
PROCEDURE

bioelectric impedance analysis

Undergo bioelectric impedance analysis

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01869777 - Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia | Biotech Hunter | Biotech Hunter